Skip to NavigationSkip to content

Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

Published on 09/12/19 at 04:02pm

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients with haemophilia A through to 44 weeks following treatment.

The trial data from April showed that two patients administered with the highest dose of SB-525 had reached normal FVIII levels. More results in July from 10 subjects demonstrated a dose-dependent increase in FVIII activity levels.

At the American Society of Hematology (ASH) the updated results from the Phase 1/2 Alta study were presented. The findings were from 11 patients treated across four ascending dose cohorts, with five subjects receiving the highest does of 3e13 vg/kg. The results show that patients receiving this dose achieved normal range FVIII activity within five to seven weeks of treatment with SB-525.

Barbara Konkle, Professor of Medicine at University of Washington and a Principal Investigator of the Alta study, said: “It is important to continue to follow these patients to determine whether these results are sustained in the longer term as the combination of a favourable safety profile coupled with sustained expression at a level that prevents bleeding and allows normal activity will be the hallmark of a successful gene therapy for haemophilia A.”

Application to Pfizer is expected to be completed in the first quarter of 2020, and Sangamo has completed the manufacturing technology transfer and initiated the transfer of the Investigational New Drug. Pfizer is enrolling patients in the Phase 3 lead-in study. This data will provide a baseline for patients who will be enrolled into the Phase 3 trial.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches